Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.
Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.
复制标题
DOI：
10.1002/lary.25808
复制
发表时间：
2016-05
期刊：
影响因子：
--
通讯作者：
Cohen MS
中科院分区：
文献类型：
--
作者：
Sim MW;Grogan PT;Subramanian C;Bradford CR;Carey TE;Forrest ML;Prince ME;Cohen MS
To evaluate the efficacy of peritumoral hyaluronic acid-cisplatin therapy in a murine model of laryngeal squamous cell carcinoma and to evaluate its effect on cancer stem cells. An orthotopic murine study utilizing UMSCC-12 laryngeal cancer cells was conducted in randomized controlled fashion with three treatment arms: saline, systemic cisplatin, and peritumoral HA-cisplatin. UMSCC-12 laryngeal cancer cells were inoculated into the buccal mucosa of athymic nude mice followed by weekly treatment with saline, systemic cisplatin, or peritumoral HA-cisplatin for 3 weeks. Tumor response and animal weight was monitored and change in CD44 proportion was analyzed ex vivo. HA-cisplatin demonstrated superior antitumor efficacy and greater reduction in CD44 positivity on ex vivo analysis. Peritumoral nanoconjugated HA-cisplatin provides superior antitumor efficacy compared to standard cisplatin therapy in an in vivo laryngeal cancer model. There was also selective targeting of CD44+ cancer cells with HA-cisplatin. This therapeutic strategy could represent the first selective laryngeal CSC-targeted therapy. Further preclinical investigation is warranted to evaluate its role for locally advanced head and neck cancer treatment.
